Daily GLP-1 tablets are accelerating the shift from injections to easier treatments.
Drugmakers expect the change to expand a market that could reach $200bn this decade.
Novo Nordisk launched the first oral version of Wegovy in the US in December.
Early demand was strong, with tens of thousands of weekly prescriptions.
Patients switching from jabs say pills offer steadier appetite control and greater convenience.
Cost still shapes choices.
Some users moved to tablets after insurance stopped covering injections such as Zepbound.
Tablets are cheaper, easier to store and more acceptable for people who avoid needles.
Eli Lilly will soon launch a rival pill, intensifying competition.
Oral drugs are slightly less effective than injections but attract new users with milder obesity.
Wider insurance coverage in the US is expected to boost uptake further.
Global obesity continues to rise and millions remain untreated.
Analysts call the pill rollout a pivotal moment that could push weight-loss medicine into the healthcare mainstream.
